Please assess the completion status of the following clinical trial:

Trial Title: A Long-term Extension Study of E2007 in Patients With Refractory Partial Seizures Uncontrolled With Other Anti-Epileptic Drugs (AEDs)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~1. Patients who consent to the study entry on their free will before starting any trial-related activities.~2. Patients who participated in Study 231 and completed the required evaluation period (10 weeks).~3. Patients who are certainly and voluntarily able to participate in this study and record their seizures by themselves or have family members or caregivers (or nurses, if hospitalized) record the seizures. Patients who wish to continue perampanel treatment and necessitate receiving the long- term administration judged by the investigator or sub-investigator.~Exclusion criteria:~1. Pregnant or lactating women, women of child-bearing potential, women willing to become pregnant.~2. Patients who are ineligible judged by the investigator or sub investigator in light of medical history or complication at enrollment in treatment period.~3. Patients who operate heavy equipment or drive should not be recruited into the study.~4. Patients who are ineligible for study entry judged by the investigator or sub-investigator.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Perampanel (Type: EXPERIMENTAL): Participants were treated with the perampanel dose that was administered in maintenance period of Study E2007-J081-231 (Study 231) \[NCT00849212\]. In some instances, a 1-step down-titration from the viewpoint of safety and up-titration to the maintenance dose of Study 231 was allowed. In general, 1 to 6 tablets of perampanel was administered orally as a 2-milligram (mg) tablet (2 mg to 12 mg) once daily before bedtime (under fed conditions as much as possible).~The investigator, or subinvestigator, was allowed to complete the treatment by tapering the study drug after end of treatment or discontinuation (Follow-up Period), as appropriate. The taper period was 4 weeks at the longest.

Based on this trial design, predict the completion outcome and termination type (if applicable).